Skip to search formSkip to main contentSkip to account menu

Thymitaq

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

nolatrexednolatrexed dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
Highly Cited
2003
Highly Cited
2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
BACKGROUND Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can… 
Review
2001
Review
2001
Thymitaq (Zarix).
Zarix is developing Thymitaq (nolatrexed dihydrochloride) for the potential treatment of cancer. It is conducting a phase III… 
2001
2001
Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model.
UNLABELLED We report improved incorporation of the radiolabeled-thymidine analog [125I/131I]5-iodo-2'-deoxyuridine ([125I/131I… 
1999
1999
Ab initio studies of some amino acid residue complexes with 4-mercaptopyridine as a model for thymitaq (AG337), an inhibitor of thymidylate synthase.
The complex formed by isopentane, as a model for the isoleucine residue present in the wild-type thymidylate synthase, with 4… 
1998
1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
PURPOSE A phase I, multicenter trial of the thymidylate synthase (TS) inhibitor THYMITAQ (nolatrexed dihydrochloride; Agouron… 
1998
1998
Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ TM ) and paclitaxel in patients with advanced solid tumours
1997
1997
Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors
Purpose: To establish the maximum tolerated dose (MTD), dose-limiting and other major toxicities and the major pharmacokinetic… 
Review
1997
Review
1997
[Head and neck cancer].
Phase II study of nedaplatin (NDP), a new derivative of cisplatin, was completed in 1990, so this agent is now commercially… 
1996
1996
Synergy between the non‐classical thymidylate synthase inhibitor AG337 (ThymitaqR) and cisplatin in human colon and ovarian cancer cells
AG337 is a recent non-classical thymidylate synthase inhibitor with promising activity and manageable toxicity in phase I… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)